McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, …
Industry Peers
Medical Distribution| Headline | Source | Time |
|---|---|---|
Older | ||
McKesson (MCK) Declares Quarterly Dividend, Is The Stock Still Undervalued? McKesson (MCK) has announced a quarterly dividend of $0.94 per share, payable on October 1, 2026. Both the ex dividend and record dates are set for September 1, 2026, drawing fresh attention to the stock. See our latest analysis for McKesson. At a latest share price of $840.90, McKesson has seen a 1 day share price return of 1.99% and a 1 month share price return of 9.70%, while its 1 year total shareholder return of 18.61% and 5 year total shareholder return of 323.86% indicate solid longer... | ||
McKesson (MCK) Stock May Still Be A Bargain After A 324% Run McKesson stock has logged a very strong 323.9% return over the past five years, yet the latest valuation checks still flag it as screening on the cheap side. This raises the question of how much of the story is already reflected in the current US$840.90 share price. Over five years, McKesson has returned 323.9%, which puts long term holders in a strong position and makes today’s entry point more sensitive to the valuation starting point. For valuation, the key support is the company’s role... | ||
Rising Dividend and Buybacks Might Change The Case For Investing In McKesson (MCK) Earlier this week, McKesson Corporation announced a quarterly dividend of US$0.94 per share, payable on October 1, 2026, to shareholders of record as of the September 1, 2026 ex-dividend and record date. This higher payout highlights how McKesson is combining dividend growth with its existing share repurchase efforts, reinforcing management’s confidence in the company’s earnings power. Against this backdrop of a higher quarterly dividend, we’ll now examine how the announcement interacts with... | ||
Here's Why You Should Add Cencora Stock to Your Portfolio Now COR's specialty expansion, supply-chain investments and international momentum support growth, though pricing, debt and regulation pose risks. | ||
Revvity Develops High-Throughput T-SPOT.TB Platform for Clinical Labs RVTY's T-SPOT A201 targets a 2027 launch, promising high-throughput latent TB testing with greater lab efficiency and scalability. | ||
1 S&P 500 Stock on Our Buy List and 2 Facing Challenges The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors. | ||
WST Stock Jumps on Q2 Earnings & Sales Beat, EPS View Up on HVP Growth WST tops Q2 earnings and revenue estimates, lifts its 2026 EPS outlook and sees shares surge as high-value products fuel strong growth. | ||
Here's Why McKesson (MCK) Fell More Than Broader Market In the most recent trading session, McKesson (MCK) closed at $814.04, indicating a -1.79% shift from the previous trading day. | ||
Is Trending Stock McKesson Corporation (MCK) a Buy Now? Recently, Zacks.com users have been paying close attention to McKesson (MCK). This makes it worthwhile to examine what the stock has in store. | ||
Here's How Much You'd Have If You Invested $1000 in McKesson a Decade Ago Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards. | ||
McKesson (MCK) Declines More Than Market: Some Information for Investors McKesson (MCK) closed at $831.46 in the latest trading session, marking a -1.18% move from the prior day. | ||
McKesson's Q1 2027 Earnings: What to Expect McKesson is expected to announce its second-quarter earnings next month, and Wall Street forecasts a double-digit rise in its profits. | ||
Here’s Why McKesson Corporation (MCK) Slid in Q2 Janus Henderson Investors, an investment management company, released its second-quarter 2026 investor letter for the “Global Sustainable Equity Fund”. A copy of the letter can be downloaded here. Global equities experienced a robust quarter, with the Fund returning 16.17%, outperforming the Index’s 13.16% gain and the Peer Group’s 12.98% return. An overweight in information technology, particularly AI […] | ||
Cheniere Energy (LNG) Appoints Britt Vitalone As It Reworks Key Credit Lines Cheniere Energy (NYSE:LNG) has appointed Britt Vitalone, a veteran finance leader with experience at McKesson and Align Technology, to its Board of Directors. Vitalone will serve on both the Audit and Compensation Committees, adding expertise in corporate finance, capital allocation, and governance. The company has also adjusted several revolving credit facilities, including higher commitments, extended maturities, and updated terms for subsidiary credit lines. These governance and credit... | ||
2 Profitable Stocks Worth Investigating and 1 We Turn Down While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”. | ||
McKesson (MCK) Stock Dips While Market Gains: Key Facts McKesson (MCK) closed at $803.37 in the latest trading session, marking a -1.1% move from the prior day. | ||
Zacks Industry Outlook McKesson, Cardinal, West Pharmaceutical, Align and Henry McKesson, Cardinal, West Pharmaceutical, Align and Henry have been highlighted in this Industry Outlook article. | ||
5 Medical Supply Stocks to Buy Amid Strong Industry Tailwinds Here, we highlight five dental supplies stocks, MCK, CAH, WST, ALGN and HSIC, which are well positioned to generate wealth for investors amid improving industry prospect. | ||